{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:03:44Z","timestamp":1789884224188,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jaad.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T07:30:26Z","timestamp":1447140626000},"page":"134-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":151,"title":["Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)"],"prefix":"10.1016","volume":"74","author":[{"given":"Phoebe","family":"Rich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongdean","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.09.001_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the US: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jaad.2015.09.001_bib2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2015.09.001_bib3","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/jid.2010.165","article-title":"A subpopulation of CD163-positive macrophages is classically activated in psoriasis","volume":"130","author":"Fuentes-Duculan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-4632.2011.05154.x","article-title":"The roles of cells and cytokines in the pathogenesis of psoriasis","volume":"51","author":"Coimbra","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00002018-200225130-00003","article-title":"Comparative tolerability of systemic treatments for plaque-type psoriasis","volume":"25","author":"McClure","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2015.09.001_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br J Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.09.001_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000316179","article-title":"Treatment and management of psoriasis with nail involvement: a focus on biologic therapy","volume":"221","author":"Langley","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.09.001_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","article-title":"Treatment of nail psoriasis: best practice recommendations from the medical board of the National Psoriasis Foundation","volume":"151","author":"Crowley","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1468-3083.2009.03372.x","article-title":"Scalp psoriasis: European consensus on grading and treatment algorithm","volume":"23","author":"Ortonne","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.09.001_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"Nestle","year":"2009","journal-title":"Psoriasis. N Engl J Med"},{"key":"10.1016\/j.jaad.2015.09.001_bib13","first-page":"912","article-title":"Scalp psoriasis: an overview of the disease and available therapies","volume":"9","author":"Crowley","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.09.001_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-3083.2012.04525.x","article-title":"Adherence to topical treatment in psoriasis: a systematic literature review","volume":"26","author":"Devaux","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.09.001_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000246274","article-title":"Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients","volume":"193","author":"de Jong","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.09.001_bib16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jaad.2015.09.001_bib17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2015.09.001_bib18","series-title":"Otezla [package insert]","year":"2014"},{"key":"10.1016\/j.jaad.2015.09.001_bib19","series-title":"Otezla [summary of product characteristics]","year":"2015"},{"key":"10.1016\/j.jaad.2015.09.001_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib21","doi-asserted-by":"crossref","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. http:\/\/dx.doi.org\/10.1111\/bjd.14164. Published online September 10, 2015.","DOI":"10.1111\/bjd.14164"},{"key":"10.1016\/j.jaad.2015.09.001_bib22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.09.001_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2012.681017","article-title":"Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council","volume":"24","author":"Kragballe","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.09.001_bib24","first-page":"CD007633","article-title":"Interventions for nail psoriasis","volume":"1","author":"de Vries","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl","key":"10.1016\/j.jaad.2015.09.001_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000316171","article-title":"Nailing down the genetic and immunological basis for psoriatic disease","volume":"221","author":"McGonagle","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.09.001_bib26","unstructured":"Reich K, Papp K, Gordon KB, et\u00a0al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized, controlled trials (ESTEEM 1 and 2). Presented orally at: the European Academy of Dermatology and Venereology (EADV); October 8-12, 2014; Amsterdam, The Netherlands."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215021398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215021398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:25Z","timestamp":1759271725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215021398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0190962215021398"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}